SCHEMBL14722794

SCHEMBL14722794

COCCN1C(=O)c2ccccc2C(C(=O)Nc2ccc(OC)c(Cl)c2)C1c1cccs1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 4/20 0.47
MAPT P10636 3/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 3/20 0.44
NPSR1 Q6W5P4 3/20 0.44
MEN1 O00255 2/20 0.44
CYP3A4 P08684 1/20 0.44
GAA P10253 4/20 0.44
NPC1 O15118 2/20 0.44
GLA P06280 2/20 0.44
RAB9A P51151 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
TP53 P04637 1/20 0.42
MDM2 Q00987 1/20 0.42
MALT1 Q9UDY8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15960759 1.00 CYP2C9 (0.52) CYP2C9CYP2C19ALDH1A1KDM4EMAPT
SCHEMBL2340681 0.94 CYP2C9 (0.52) CYP2C9CYP2C19ALDH1A1KDM4EMAPT
SCHEMBL2335500 0.93 CYP2C9 (0.54) CYP2C9CYP2C19ALDH1A1KDM4EMAPT
SCHEMBL2333455 0.93 CYP2C9 (0.54) CYP2C9CYP2C19ALDH1A1KDM4EMAPT
SCHEMBL2338076 0.91 CYP2C9 (0.51) CYP2C9CYP2C19ALDH1A1KDM4EMAPT
SCHEMBL2336737 0.90 CYP2C9 (0.56) CYP2C9CYP2C19ALDH1A1KDM4EMAPT
SCHEMBL2337106 0.89 CYP2C9 (0.52) CYP2C9CYP2C19ALDH1A1KDM4EMAPT
SCHEMBL2335941 0.88 CYP2C9 (0.53) CYP2C9CYP2C19ALDH1A1KDM4EMAPT
SCHEMBL2339912 0.88 CYP2C9 (0.53) CYP2C9CYP2C19ALDH1A1KDM4EMAPT
SCHEMBL2334232 0.87 CYP2C9 (0.53) CYP2C9CYP2C19ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2748147-A1 SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4-TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES St. Jude Children's Research Hospital (US) 2014-07-02 EP claimed
WO-2013027196-A9 SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4- TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2013-04-18 WO claimed
WO-2013027196-A1 SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4- TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2013-02-28 WO claimed
EP-2748147-B1 SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4-TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES ST JUDE CHILDREN'S RES HOSPITAL (US) 2017-08-02 EP disclosed
US-9416124-B2 Substituted 2-alkyl-1-OXO-N-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-08-16 US disclosed
US-20140235593-A1 SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4-TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-08-21 US disclosed
CN-103930404-A Substituted 2-alkyl-1-oxo-N-phenyl-3-heteroaryl-1, 2,3, 4-tetrahydroisoquinoline-4-amides for use in a method of treatment against malaria ST JUDE CHILDRENS RES HOSPITAL 2014-07-16 CN disclosed
EP-2748147-A1 SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4-TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES St. Jude Children's Research Hospital (US) 2014-07-02 EP disclosed
WO-2013027196-A9 SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4- TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2013-04-18 WO disclosed
WO-2013027196-A1 SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4- TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235593-A1 SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4-TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES QTRT1, GLS2, QTRT2 CYP2C9 472/4885CYP2C19 450/4885ALDH1A1 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.